FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 316:764-770 March 26, 1987 Number 13 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

A change in the formulation of the levothyroxine preparation Synthroid (Flint) in 1982 prompted us to reevaluate the replacement dose of this drug in 19 patients with hypothyroidism. The dose was titrated monthly until thyrotropin levels became normal. The mean replacement dose (+/- SD) was 112 +/- 19 micrograms per day, significantly less (P less than 0.001) than the dose of an earlier formulation--169 +/- 66 micrograms per day--used in a similar study (Stock JM, et al. N Engl J Med 1974; 290:529-33). The fractional gastrointestinal absorption of a tablet of the current formulation is 81 percent, considerably higher than the earlier estimate of 48 percent. Using high-performance liquid chromatographic analysis, we found that the current tablet contains the amount of thyroxine stated by the manufacturer. By measuring the bioavailability of the earlier type of tablet in five patients, we inferred that the strength of the previous tablet had been overestimated. In the present study, the thyrotropin levels of patients on replacement therapy returned to normal when serum triiodothyronine concentrations were not significantly different from those of controls (122 vs. 115 ng per deciliter [1.87 vs. 1.77 nmol per liter]), but when serum thyroxine levels were significantly above those of controls (11.3 vs. 8.7 micrograms per deciliter [145 vs. 112 nmol per liter], P less than 0.001). These findings suggest the possibility that in humans, serum triiodothyronine may play a more important part than serum thyroxine in regulating the serum thyrotropin concentration.

This article has been cited by other articles:

• Jonklaas, J., Davidson, B., Bhagat, S., Soldin, S. J. (2008). Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy. JAMA 299: 769-777 [Abstract] [Full Text]  
• Cooper, D. S. (2008). Thyroxine Monotherapy After Thyroidectomy: Coming Full Circle. JAMA 299: 817-819 [Full Text]  
• Checchi, S., Montanaro, A., Pasqui, L., Ciuoli, C., De Palo, V., Chiappetta, M. C., Pacini, F. (2008). L-Thyroxine Requirement in Patients with Autoimmune Hypothyroidism and Parietal Cell Antibodies. J. Clin. Endocrinol. Metab. 93: 465-469 [Abstract] [Full Text]  
• Slawik, M., Klawitter, B., Meiser, E., Schories, M., Zwermann, O., Borm, K., Peper, M., Lubrich, B., Hug, M. J., Nauck, M., Olschewski, M., Beuschlein, F., Reincke, M. (2007). Thyroid Hormone Replacement for Central Hypothyroidism: A Randomized Controlled Trial Comparing Two Doses of Thyroxine (T4) with a Combination of T4 and Triiodothyronine. J. Clin. Endocrinol. Metab. 92: 4115-4122 [Abstract] [Full Text]  
• Varughese, G I, Tahrani, A A, Davis, J, Clayton, R N, Hanna, F W F (2006). Caveats in treating thyroid disease: practical implications. JRSM 99: 582-583 [Full Text]  
• Centanni, M., Gargano, L., Canettieri, G., Viceconti, N., Franchi, A., Fave, G. D., Annibale, B. (2006). Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis.. NEJM 354: 1787-1795 [Abstract] [Full Text]  
• Surks, M. I., Goswami, G., Daniels, G. H. (2005). The Thyrotropin Reference Range Should Remain Unchanged. J. Clin. Endocrinol. Metab. 90: 5489-5496 [Abstract] [Full Text]  
• Roos, A., Linn-Rasker, S. P., van Domburg, R. T., Tijssen, J. P., Berghout, A. (2005). The Starting Dose of Levothyroxine in Primary Hypothyroidism Treatment: A Prospective, Randomized, Double-blind Trial. Arch Intern Med 165: 1714-1720 [Abstract] [Full Text]  
• Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., de Escobar, G. M. (2005). Treatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine. J. Clin. Endocrinol. Metab. 90: 4946-4954 [Abstract] [Full Text]  
• Escobar-Morreale, H. F., Botella-Carretero, J. I., Gomez-Bueno, M., Galan, J. M., Barrios, V., Sancho, J. (2005). Thyroid Hormone Replacement Therapy in Primary Hypothyroidism: A Randomized Trial Comparing L-Thyroxine plus Liothyronine with L-Thyroxine Alone. ANN INTERN MED 142: 412-424 [Abstract] [Full Text]  
• Lazarus, J H (2005). Congenital hypothyroidism. Arch. Dis. Child. 90: 112-113 [Full Text]  
• Santini, F., Pinchera, A., Marsili, A., Ceccarini, G., Castagna, M. G., Valeriano, R., Giannetti, M., Taddei, D., Centoni, R., Scartabelli, G., Rago, T., Mammoli, C., Elisei, R., Vitti, P. (2005). Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases. J. Clin. Endocrinol. Metab. 90: 124-127 [Abstract] [Full Text]  
• Walsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., Cussons, A. J. (2003). Combined Thyroxine/Liothyronine Treatment Does Not Improve Well-Being, Quality of Life, or Cognitive Function Compared to Thyroxine Alone: A Randomized Controlled Trial in Patients with Primary Hypothyroidism. J. Clin. Endocrinol. Metab. 88: 4543-4550 [Abstract] [Full Text]  
• Nordyke, R. A., Reppun, T. S., Madanay, L. D., Woods, J. C., Goldstein, A. P., Miyamoto, L. A. (1998). Alternative Sequences of Thyrotropin and Free Thyroxine Assays for Routine Thyroid Function Testing: Quality and Cost. Arch Intern Med 158: 266-272 [Abstract] [Full Text]  
• Peran, S., Garriga, M. J., Morreale de Escobar, G., Asuncion, M., Peran, M. (1997). Increase in Plasma Thyrotropin Levels in Hypothyroid Patients during Treatment due to a Defect in the Commercial Preparation. J. Clin. Endocrinol. Metab. 82: 3192-3195 [Abstract] [Full Text]  
• de Frias, E. C., Ruibal, J.L., Reverte, F., Bueno, G. (1993). Evolution of Height and Bone Age in Primary Congenital Hypothyroidism. CLIN PEDIATR 32: 426-432 [Abstract]